Earnings Releases·Nov 4, 2026, 4:12 PM ET

Caris Life Sciences — Third Quarter 2026 Earnings Summary

Revenue grew 27% year-over-year to $275.4 million, driven by a 27% increase in molecular profiling services and a 21% rise in clinical cases to 61,500, though net income declined to $15.3 million from $24.3 million due to a 42% surge in operating expenses.
Full-year 2026 revenue guidance was raised to $1.04–$1.05 billion (28–29% growth), while gross margin contracted to 66% and free cash flow turned negative at $(39.7) million compared to $55.3 million in the prior year period.
The company announced a new share repurchase program up to $100.0 million, repaid the $406.3 million 2023 term loan in full, and raised $393.5 million via a new 2026 term loan, resulting in $665.3 million in total cash and restricted cash.
Strategic milestones include the targeted year-end 2026 launch of Caris Confirm for minimal residual disease, the rollout of enhanced Caris Assure with 40,000x sequencing depth, and the publication of validation for the Caris AI Insights™ pancreatic cancer signature.